TL
BMRN icon

TrueWealth LLC’s BioMarin Pharmaceuticals BMRN Stock Holding History

TrueWealth LLC’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-155
Closed -$10K – 730
2019
Q3 		$10K Sell
155
-84
-35% -$6.47K ﹤0.01% 446
2019
Q2 		$20K Hold
239
– – 0.01% 365
2019
Q1 		$21K Hold
239
– – 0.01% 359
2018
Q4 		$20K Hold
239
– – 0.01% 360
2018
Q3 		$23K Hold
239
– – 0.01% 369
2018
Q2 		$23K Hold
239
– – 0.01% 368
2018
Q1 		$19K Sell
239
-165
-41% -$14.2K 0.01% 364
2017
Q4 		$36K Buy
+404
New +$35.1K 0.02% 318

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

TrueWealth LLC's BMRN Position: Q4 2019 in Review

TrueWealth LLC sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2019, closing a stake of 155 shares — an estimated $10K sold.

TrueWealth LLC first reported a position in BMRN in Q4 2017 and held it in 8 quarters. The position peaked at $36K in Q4 2017. 467 funds tracked by Wall St. Rank hold BMRN as of Q4 2019.

  • TrueWealth LLC reported no remaining BioMarin Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • TrueWealth LLC sold 155 BioMarin Pharmaceuticals shares in Q4 2019, an estimated $10K.
  • TrueWealth LLC first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 8 quarters.
  • TrueWealth LLC's BioMarin Pharmaceuticals position peaked at $36K in Q4 2017.
  • 467 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2019.

Based on TrueWealth LLC's 13F filing for Q4 2019, filed 22 Jan 2020.